Alzheimer's disease neuropathology is exacerbated following traumatic brain injury. Neuroprotection by co-administration of nanowired mesenchymal stem cells and cerebrolysin with monoclonal antibodies to amyloid beta peptide
by Sharma, Hari Shanker; Muresanu, Dafin F.; Castellani, Rudy J.; Nozari, Ala; Lafuente, José Vicente; Buzoianu, Anca D.; Sahib, Seaab; Tian, Z. Ryan; Bryukhovetskiy, Igor; Manzhulo, Igor; Menon, Preeti K.; Patnaik, Ranjana; Wiklund, Lars; Sharma, Aruna
Military personnel are prone to traumatic brain injury (TBI) that is one of the risk factors in developing Alzheimer's disease (AD) at a later stage. TBI induces breakdown of the bloodbrain barrier (BBB) to serum proteins into the brain and leads to extravasation of plasma amyloid beta peptide (A beta P) into the brain fluid compartments causing AD brain pathology. Thus, there is a need to expand our knowledge on the role of TBI in AD. In addition, exploration of the novel roles of nanomedicine in AD and TBI for neuroprotection is the need of the hour. Since stem cells and neurotrophic factors play important roles in TBI and in AD, it is likely that nanodelivery of these agents exert superior neuroprotection in TBI induced exacerbation of AD brain pathology. In this review, these aspects are examined in details based on our own investigations in the light of current scientific literature in the field. Our observations show that TBI exacerbates AD brain pathology and TiO2 nanowired delivery of mesenchymal stem cells together with cerebrolysin-a balanced composition of several neurotrophic factors and active peptide fragments, and monoclonal antibodies to amyloid beta protein thwarted the development of neuropathology following TBI in AD, not reported earlier.